It is trading at $12.60 just above the 50 day moving average of $10.39 and which is slightly above the 200 day moving average of $10.69. The 50 day moving average went up by +21.24% and the 200 day average was up $1.91. 269K shares changed hands on Thursday. Shares saw a steep decrease in trading volume of 47.96% under the normal average daily volume.
Traders are feeling more bullish on the company recently if you take a look at the change in short interest. The stock recorded a fall in short interest from June 15, 2017 to May 31, 2017 of -3.15%. Short shares fell from 5,721,925 to 5,541,696 over that period. With short interest at 5,541,696 and short average daily volume at 497,453, the short-interest ratio is 11.1 and the short interest percentage is 0.08% as of May 31.
Here is the rundown on market activity for Aduro Biotech, Inc. (NASDAQ:ADRO). Gregory W. Schafer, Chief Operating Officer let go of $450,400 worth of shares at an average price of $11.26 on Wed the 28th. That brings the Chief Operating Officer’s holdings to $1,362,224 as reported to the SEC. Sr. Vice President of Finance Jennifer Lew let go of 12,000 shares at an average price of $11.19 on June 28th. That brings Lew’s holdings to $476,638 as recorded in a recent Form 4 SEC filing.
President and CEO Stephen T. Isaacs sold 40,000 shares at an average price of $10.50 on Mon the 19th. The President and CEO now owns $1,092,263 of the stock per an SEC filing yesterday.
Here are a few other firms who have also updated their positions. Creative Planning reduced its stake by shedding 1,950 shares a decrease of 13.0% in the quarter. Creative Planning now holds 13,050 shares with a value of $149,000. The value of the position overall is down by 7.5%. As of the end of the quarter Daiwa Sb Investments Ltd. had sold a total of 200 shares trimming its position 1.4%. The value in dollars increased from $153,000 to $160,000 a change of 4.6% since the last quarter.
As of quarter end Bank Of Montreal /can/ had acquired 388 shares growing its stake by 50.5%. The value of the investment in (ADRO) went from $8,000 to $13,000 increasing 62.5% for the reporting period. As of quarter end Clearbridge Investments, LLC had acquired 11 shares growing its holdings by 0.0%. The value of the company’s investment in Aduro Biotech, Inc. went from $2,538,000 to $2,393,000 a change of $145,000 quarter over quarter.
Bank of America lowered the price target and downgraded the stock on March 15 changing the price target from $32.00 to $14.00 and altering the rating from “Buy” to “Underperform”. On March 15 the stock rating was downgraded from “Buy” to “Underperform” with a current price target of $14.00 by analysts at Bank of America.
On March 2 analysts at FBR Capital began coverage setting a rating of “Outperform” and setting a price target of $30.00. On December 1, 2015 the stock rating was rated “Perform” in a report from Oppenheimer a cut from the previous “Outperform” rating.
On October 20, 2015 Oppenheimer starting coverage on the stock giving it an initial rating of “Outperform” and projecting a price target of $30.00. Equity analyst Oppenheimer released its first research report on the stock with a rating of “Outperform” and a price target of $30.00.
The company is so far trading down from yesterday’s close of $12.7. As of the latest earnings report the EPS was $-1.27 and is expected to be $-1.39 for the current year with 69,913,000 shares now outstanding. Next quarter’s EPS is forecasted to be $-0.39 and the next full year EPS is anticipated to be $-1.64.
Aduro Biotech, Inc., launched on May 5, 2011, is an immunotherapy company. The Company focuses on the discovery, development and commercialization of therapies that manage the treatment of various diseases, including cancer. The Business’s product candidates from its Live, Attenuated, Double-Deleted (LADD) Listeria monocytogenes, Stimulator of Interferon Genes (STING) Pathway Activator, and B-select monoclonal antibody platforms are designed to stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies (i.e. chemotherapy and radiation), as well as other immunotherapies. Its LADD technology platform is being developed as a treatment for multiple indications, including mesothelioma, ovarian, gastric, lung and prostate cancers. Its LADD product candidate is CRS-207, which is being developed as a treatment for multiple indications, including mesothelioma, ovarian, and gastric cancers. ADU-214 and ADU-741 are product candidates in development for lung and prostate cancers, respectively. A personalized form of LADD (pLADD) is being developed utilizing tumor neoantigens that are specific to an individual patient’s tumor..